MBX Biosciences
MBX
49.55
-3.86
-7.23%
MBX Biosciences
US · MBX
#2567 by market cap
Listed 2024
49.55
-3.86
-7.23%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Company notice
4: MBX Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Pescovitz Ora H.SEC · 2026/6/5
-
Rating change
MBX Biosciences, Inc. (MBX) Gets a Buy From Mizuho SecuritiesTipRanks · 2026/8/8
-
Company notice
MBX Biosciences | 4: Statement of changes in beneficial ownership of securities-Officer Hawryluk P. KentSEC · 2026/5/9
-
Rating change
Guggenheim Maintains MBX Biosciences(MBX.US) With Buy Rating, Raises Target Price to $150Market Newswire · 2026/10/2
-
Rating change
Stifel Maintains MBX Biosciences(MBX.US) With Buy Rating, Raises Target Price to $84Market Newswire · 2026/10/12
-
Rating change
Stifel Maintains MBX Biosciences(MBX.US) With Buy Rating, Raises Target Price to $70Market Newswire · 2026/8/13
-
Company notice
4: MBX Biosciences | 4: Statement of changes in beneficial ownership of securities-Officer Hoerter Steven L.SEC · 2026/8/4
-
Company notice
MBX Biosciences | 4: Statement of changes in beneficial ownership of securities-Officer Hoerter Steven L.SEC · 2026/11/12
-
Rating change
Barclays Maintains MBX Biosciences(MBX.US) With Buy Rating, Raises Target Price to $88Market Newswire · 2026/8/7
-
Rating change
Mizuho Securities Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $91Market Newswire · 2026/8/8
-
Rating change
J.P. Morgan Maintains MBX Biosciences(MBX.US) With Buy Rating, Announces Target Price $88Market Newswire · 2026/8/21
-
Company notice
4: MBX Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Hoerter Steven L.SEC · 2026/6/5
-
Guggenheim Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $150Market Newswire · 2026/10/12
-
Rating change
LifeSci Capital Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $121Market Newswire · 2026/8/8
-
Rating change
Analysts Offer Insights on NA Companies: MBX Biosciences, Inc. (MBX), Septerna, Inc. (SEPN) and Six Flags Entertainment Corporation (FUN)TipRanks · 2026/8/13
-
Rating change
Truist Financial Maintains MBX Biosciences(MBX.US) With Buy Rating, Announces Target Price $88Market Newswire · 2026/8/10
-
HC Wainwright & Co. Initiates Coverage On MBX Biosciences With Buy Rating, Announces Price Target of $90Benzinga · 2026/11/12
-
Barclays Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $88Market Newswire · 2026/10/13
-
UBS Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $90Market Newswire · 2026/11/10
-
H.C. Wainwright Initiates MBX Biosciences(MBX.US) With Buy Rating, Announces Target Price $90Market Newswire · 2026/11/12
-
Truist Financial Maintains MBX Biosciences(MBX.US) With Buy RatingMarket Newswire · 2026/7/16
-
Rating change
Analysts Offer Insights on NA Companies: BillionToOne, Inc. Class A (BLLN) and MBX Biosciences, Inc. (MBX)TipRanks · 2026/8/7
-
Rating change
LifeSci Capital Maintains MBX Biosciences(MBX.US) With Buy Rating, Raises Target Price to $121Market Newswire · 2026/8/7
-
Company notice
MBX Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Hoerter Steven L.SEC · 2026/5/4
-
Rating change
UBS Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $90Market Newswire · 2026/7/24
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
MBX Biosciences discussion 0 comments